← Back to Clinical Trials
Recruiting NCT05830942

NCT05830942 Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05830942
Status Recruiting
Phase
Sponsor University of Florida
Condition Cognitive Dysfunction
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2024-04-15
Primary Completion 2027-04-30

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Walking ExercisePrefrontal Active tDCSPrefrontal Sham tDCS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2024-04-15 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Declines in cognitive function and walking function are highly intertwined in older adults. A therapeutic approach that combines complex (cognitively engaging) aerobic walking exercise with non-invasive electrical brain stimulation may be effective at restoring lost function. This study tests whether electrical stimulation of prefrontal brain regions is more beneficial than sham stimulation.

Eligibility Criteria

Inclusion Criteria: * Age 65+ * Objective executive function decline, based on standardized cognitive assessments. * Subjective cognitive decline, based on the question: "During the past 12 months, have you experienced confusion or memory loss that is happening more often or getting worse?" * Ability to walking independently for 6 minutes (use of cane permitted) Exclusion Criteria: * Major cognitive disorder that interferes with independence * Percentile score less than 10th percentile on standardized cognitive assessments * Medications that are thought to influence tDCS neuroplasticity. * Contraindications to tDCS or MRI.

Contact & Investigator

Central Contact

David J Clark, ScD

✉ davidclark@ufl.edu

📞 352-376-1611

Principal Investigator

David J Clark, ScD

PRINCIPAL INVESTIGATOR

University of Florida

Frequently Asked Questions

Who can join the NCT05830942 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Cognitive Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05830942 currently recruiting?

Yes, NCT05830942 is actively recruiting participants. Contact the research team at davidclark@ufl.edu for enrollment information.

Where is the NCT05830942 trial being conducted?

This trial is being conducted at Gainesville, United States, Jacksonville, United States.

Who is sponsoring the NCT05830942 clinical trial?

NCT05830942 is sponsored by University of Florida. The principal investigator is David J Clark, ScD at University of Florida. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology